Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection

T Kagawa, J Koizumi, S Kojima, N Nagata, M Numata… - Cancer, 2010 - Wiley Online Library
BACKGROUND: Radiofrequency ablation (RFA) is becoming a well‐known local therapy
for hepatocellular carcinoma (HCC). Transcatheter arterial chemoembolization (TACE) is …

Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: a multicenter analysis

…, K Numata, C Kusano, T Kagawa… - Hepatology …, 2022 - Wiley Online Library
Purpose To assess the impact of clinical factors on the safety and efficacy of atezolizumab
plus bevacizumab (ATZ + BV) treatment in patients with unresectable hepatocellular …

Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib

…, N Hattori, K Ogushi, M Morimoto, T Kagawa… - Liver cancer, 2020 - karger.com
Background: Low skeletal muscle mass is significantly associated with severe adverse events
(AEs) from chemotherapy, and low tolerability leads to decreased survival. We aimed to …

A deactivation factor of fibrogenic hepatic stellate cells induces regression of liver fibrosis in mice

…, A Kamiya, H Sumiyoshi, K Tsuruya, T Kagawa… - Hepatology, 2020 - journals.lww.com
Conclusions LVEF≤ 60% is strongly associated with higher post‐LT mortality rates in the
MELD≥ 20 group, indicating the need to appraise both LVEF and liver disease severity …

[HTML][HTML] The immunological function of extracellular vesicles in hepatitis B virus-infected hepatocytes

…, Y Yamamoto, S Yabuta, N Kurosaki, T Kagawa… - PLoS …, 2018 - journals.plos.org
Hepatitis B virus (HBV) generates large amounts of complete and incomplete viral particles.
Except for the virion, which acts as infectious particles, the function of those particles …

Analysis of 307 cases with drug‐induced liver injury between 2010 and 2018 in Japan

M Aiso, H Takikawa, K Tsuji, T Kagawa… - Hepatology …, 2019 - Wiley Online Library
Aim In order to know the present status of drug‐induced liver injury (DILI) in Japan, we present
the data of prospectively collected DILI cases between 2010 and 2018 from 27 hospitals. …

Association between immune-related adverse events and survival in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

…, K Numata, K Tsuruya, Y Arase, T Kagawa… - The …, 2023 - academic.oup.com
Background Immune checkpoint inhibitors (ICIs) are effective for advanced hepatocellular
carcinoma (HCC). However, there are few reports on the correlation between the clinical …

[HTML][HTML] Early changes in circulating FGF19 and Ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma

…, N Hattori, K Ogushi, A Nozaki, H Fukuda, T Kagawa… - Cancers, 2020 - mdpi.com
Predictive biomarkers of the response of hepatocellular carcinoma (HCC) to Lenvatinib
therapy have not yet been clarified. The aim of this study was to identify clinically significant …

[HTML][HTML] Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: lean versus overweight patients

…, Y Arase, K Shiraishi, M Suzuki, S Ieda, T Kagawa - PLoS …, 2020 - journals.plos.org
Background Many studies have investigated the prognosis of nonalcoholic fatty liver disease
(NAFLD); however, most studies had a relatively short follow-up. To elucidate the long-term …

Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more …

…, S Nakamura, M Morimoto, T Kagawa… - Hepatology …, 2021 - Wiley Online Library
Aims To assess the safety, efficacy, and prognostic impact of clinical factors associated with
lenvatinib treatment in highly advanced hepatocellular carcinoma (HCC) with tumor …